Esophagogastric cancer: Targeted agents Journal Article
| Authors: | Ku, G. Y.; Ilson, D. H. |
| Article Title: | Esophagogastric cancer: Targeted agents |
| Abstract: | Because of the poor prognosis for patients with locally advanced and metastatic esophageal, gastroesophageal junction and gastric cancers, increasing attention has focused on the integration of targeted agents into current therapies. The molecular targets of these agents include epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) or its receptor, cyclooxygenase-2 (COX-2), mammalian target of rapamycin (mTOR) and components and regulators of the cell cycle. In this review article, we briefly discuss pre-clinical data and the rationale for targeting these pathways and summarize the results of clinical trials to-date, including completed and ongoing phase III evaluations. © 2009 Elsevier Ltd. |
| Keywords: | survival rate; unclassified drug; gene mutation; clinical trial; drug tolerability; fatigue; neutropenia; review; squamous cell carcinoma; sorafenib; bevacizumab; cisplatin; erlotinib; fluorouracil; placebo; sunitinib; diarrhea; drug dose comparison; gastrointestinal hemorrhage; hypertension; liver cell carcinoma; nonhuman; side effect; skin toxicity; solid tumor; antineoplastic agents; clinical trials as topic; alpha interferon; capecitabine; gemcitabine; paclitaxel; pancreas cancer; drug megadose; colorectal cancer; adenocarcinoma; gastrointestinal stromal tumor; imatinib; carboplatin; unindexed drug; chemoprophylaxis; progression free survival; drug eruption; breast cancer; anemia; bone marrow suppression; bleeding; esophagitis; heart disease; lung non small cell cancer; stomatitis; thrombocytopenia; epidermal growth factor receptor; continuous infusion; cetuximab; kidney carcinoma; cancer resistance; docetaxel; irinotecan; monoclonal antibody; panitumumab; drug dose escalation; febrile neutropenia; acetylsalicylic acid; celecoxib; heart failure; heart infarction; thromboembolism; folinic acid; gefitinib; vascular endothelial growth factor; esophagus resection; stomach cancer; epirubicin; targeted therapy; colon perforation; trastuzumab; tyrosine kinase inhibitor; oxaliplatin; esophagus cancer; hand foot syndrome; heart left ventricle ejection fraction; triacylglycerol lipase blood level; esophageal adenocarcinoma; stomach adenocarcinoma; anaphylaxis; digestive system perforation; stomach neoplasms; everolimus; proteinuria; lapatinib; artery thrombosis; esophageal neoplasms; head and neck carcinoma; esophageal cancer; esophageal squamous cell carcinoma; marimastat; venous thromboembolism; gastric cancer; matuzumab; lung hemorrhage; molecularly targeted therapy; stomach perforation; gastroesophageal cancer; afinitor; emd 7200; esomeprazole; barrett esophagus; gastroesophageal junction adenocarcinoma |
| Journal Title: | Cancer Treatment Reviews |
| Volume: | 36 |
| Issue: | 3 |
| ISSN: | 0305-7372 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2010-05-01 |
| Start Page: | 235 |
| End Page: | 248 |
| Language: | English |
| DOI: | 10.1016/j.ctrv.2009.12.009 |
| PUBMED: | 20122806 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 2" - "Export Date: 20 April 2011" - "CODEN: CTRED" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work